Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
Standard
Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. / Wikman, Harriet; Sielaff-Frimpong, Bettina; Kropidlowski, Jolanthe; Witzel, Isabell; Milde-Langosch, Karin; Sauter, Guido; Westphal, Manfred; Lamszus, Katrin; Pantel, Klaus.
in: PLOS ONE, Jahrgang 7, Nr. 10, 10, 2012, S. 47537.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
AU - Wikman, Harriet
AU - Sielaff-Frimpong, Bettina
AU - Kropidlowski, Jolanthe
AU - Witzel, Isabell
AU - Milde-Langosch, Karin
AU - Sauter, Guido
AU - Westphal, Manfred
AU - Lamszus, Katrin
AU - Pantel, Klaus
PY - 2012
Y1 - 2012
N2 - The occurrence of brain metastases among breast cancer patients is currently rising with approximately 20-25% incidence rates, underlining the importance of the identification of new therapeutic and prognostic markers. We have previously screened for new markers for brain metastasis by array CGH. We found that loss of 11p15 is common among these patients. In this study, we investigated the clinical significance of loss of 11p15 in primary breast cancer (BC) and breast cancer brain metastases (BCBM). 11p15 aberration patterns were assessed by allelic imbalance (AI) analysis in primary BC (n = 78), BCBM (n = 21) and metastases from other distant sites (n = 6) using six different markers. AI at 11p15 was significantly associated with BCBM (p = 0.002). Interestingly, a subgroup of primary BC with a later relapse to the brain had almost equally high AI rates as the BCBM cases. In primary BC, AI was statistically significantly associated with high grade, negative hormone receptor status, and triple-negative (TNBC) tumors. Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr
AB - The occurrence of brain metastases among breast cancer patients is currently rising with approximately 20-25% incidence rates, underlining the importance of the identification of new therapeutic and prognostic markers. We have previously screened for new markers for brain metastasis by array CGH. We found that loss of 11p15 is common among these patients. In this study, we investigated the clinical significance of loss of 11p15 in primary breast cancer (BC) and breast cancer brain metastases (BCBM). 11p15 aberration patterns were assessed by allelic imbalance (AI) analysis in primary BC (n = 78), BCBM (n = 21) and metastases from other distant sites (n = 6) using six different markers. AI at 11p15 was significantly associated with BCBM (p = 0.002). Interestingly, a subgroup of primary BC with a later relapse to the brain had almost equally high AI rates as the BCBM cases. In primary BC, AI was statistically significantly associated with high grade, negative hormone receptor status, and triple-negative (TNBC) tumors. Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr
KW - Adult
KW - Humans
KW - Female
KW - Middle Aged
KW - Recurrence
KW - Gene Expression Regulation, Neoplastic
KW - Neoplasm Metastasis
KW - Tumor Markers, Biological/metabolism
KW - Intracellular Signaling Peptides and Proteins/genetics/metabolism
KW - Brain Neoplasms/pathology/secondary
KW - Breast Neoplasms/genetics/metabolism/pathology
KW - Chromosomes, Human, Pair 11/genetics
KW - Adult
KW - Humans
KW - Female
KW - Middle Aged
KW - Recurrence
KW - Gene Expression Regulation, Neoplastic
KW - Neoplasm Metastasis
KW - Tumor Markers, Biological/metabolism
KW - Intracellular Signaling Peptides and Proteins/genetics/metabolism
KW - Brain Neoplasms/pathology/secondary
KW - Breast Neoplasms/genetics/metabolism/pathology
KW - Chromosomes, Human, Pair 11/genetics
U2 - 10.1371/journal.pone.0047537
DO - 10.1371/journal.pone.0047537
M3 - SCORING: Journal article
VL - 7
SP - 47537
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 10
M1 - 10
ER -